MX2022001013A - Degradador selectivo del receptor de estrogeno. - Google Patents

Degradador selectivo del receptor de estrogeno.

Info

Publication number
MX2022001013A
MX2022001013A MX2022001013A MX2022001013A MX2022001013A MX 2022001013 A MX2022001013 A MX 2022001013A MX 2022001013 A MX2022001013 A MX 2022001013A MX 2022001013 A MX2022001013 A MX 2022001013A MX 2022001013 A MX2022001013 A MX 2022001013A
Authority
MX
Mexico
Prior art keywords
estrogen receptor
selective estrogen
receptor degrader
chromen
enyl
Prior art date
Application number
MX2022001013A
Other languages
English (en)
Inventor
Jayraj Dilipbhai Aradhye
Bhavesh Mohanbhai Panchal
Biswajit Samanta
Ranjan Kumar Pal
Trinadha Rao Chitturi
Sandeep Pankajkumar Pathak
Kaushik Dhanjibhai Prajapati
Original Assignee
Sun Pharma Advanced Res Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharma Advanced Res Co Ltd filed Critical Sun Pharma Advanced Res Co Ltd
Publication of MX2022001013A publication Critical patent/MX2022001013A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un degradador selectivo del receptor de estrógeno (SERD), un compuesto 3-(3,5-difluorofenil)-2-[4-[(E)-3-[3-(fluorometil)azetid in-1-il]prop-1-enil]fenil]-4-metil-2H-cromen-7-ol y su enantiómero S, (2S)-3-(3,5-difluorofenil)-2-[4-[(E)-3-[3-(fluorome til)azetidin-1-il]prop-1-enil]fenil]-4-metil-2H-cromen-7-ol, o sales farmacéuticamente aceptables de estos. También se proporcionan procesos para su preparación. También se proporciona el uso de estos compuestos para el tratamiento de enfermedades relacionadas con la modulación de los receptores de estrógeno, tales como el cáncer de mama positivo para ER.
MX2022001013A 2019-07-22 2020-07-22 Degradador selectivo del receptor de estrogeno. MX2022001013A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN201921029554 2019-07-22
PCT/IB2020/056914 WO2021014386A1 (en) 2019-07-22 2020-07-22 Selective estrogen receptor degrader

Publications (1)

Publication Number Publication Date
MX2022001013A true MX2022001013A (es) 2022-02-22

Family

ID=71842730

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001013A MX2022001013A (es) 2019-07-22 2020-07-22 Degradador selectivo del receptor de estrogeno.

Country Status (14)

Country Link
US (2) US11014915B2 (es)
EP (1) EP4003525A1 (es)
JP (1) JP2022541938A (es)
KR (1) KR20220046586A (es)
CN (1) CN114302879A (es)
AU (1) AU2020317099A1 (es)
BR (1) BR112022001285A2 (es)
CA (1) CA3148592A1 (es)
CL (1) CL2022000156A1 (es)
IL (1) IL290036A (es)
MX (1) MX2022001013A (es)
PE (1) PE20221588A1 (es)
WO (1) WO2021014386A1 (es)
ZA (1) ZA202201157B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR116300A1 (es) * 2018-09-07 2021-04-21 Sanofi Sa Proceso para la preparación de 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-dihidro-7h-benzo[7]anuleno-2-carboxilato de metilo
KR20220046586A (ko) * 2019-07-22 2022-04-14 썬 파마 어드밴스트 리서치 컴패니 리미티드 선택적 에스트로겐 수용체 분해제
KR20240135862A (ko) * 2022-02-01 2024-09-12 일라이 릴리 앤드 캄파니 선택적 에스트로겐 수용체 분해제의 제조 방법

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5395842A (en) 1988-10-31 1995-03-07 Endorecherche Inc. Anti-estrogenic compounds and compositions
DE69023906T2 (de) 1990-08-09 1996-04-11 Council Scient Ind Res Benzopyrane und Verfahren zu deren Herstellung.
US6060503A (en) 1991-12-02 2000-05-09 Endorecherche, Inc. Benzopyran-containing compounds and method for their use
US5407947A (en) 1993-11-05 1995-04-18 Eli Lilly And Company Methods for inhibiting bone loss using pyrolidine and piperidine substituted benzopyrans
US5389646A (en) 1993-12-30 1995-02-14 Zymogenetics, Inc. Methods for treatment and prevention of bone loss using 2,3-benzopyrans
AU8102398A (en) 1997-07-09 1999-02-08 Central Drug Research Institute (dl)-2,3-diaryl-2h-1-benzopyrans
DE10013782A1 (de) 2000-03-15 2001-10-18 Schering Ag 4-Fluoralkyl-2H-benzopyrane mit antiestrogener Wirksamkeit, Verfahren zu ihrer Herstellung, pharmazeutische Präparate, die diese enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
KR101698238B1 (ko) 2010-06-10 2017-01-19 세라곤 파마슈티컬스, 인크. 에스트로겐 수용체 조정제 및 이의 용도
SG11201403002RA (en) * 2011-12-14 2014-07-30 Seragon Pharmaceuticals Inc Fluorinated estrogen receptor modulators and uses thereof
AU2012353660A1 (en) 2011-12-16 2014-06-12 Olema Pharmaceuticals, Inc. Novel benzopyran compounds, compositions and uses thereof
EP3010501B1 (en) 2013-06-19 2021-11-03 Seragon Pharmaceuticals, Inc. Estrogen receptor modulator and uses thereof
EP3010502B1 (en) 2013-06-19 2018-11-21 Seragon Pharmaceuticals, Inc. Azetidine estrogen receptor modulators and uses thereof
WO2014203132A1 (en) 2013-06-19 2014-12-24 Olema Pharmaceuticals, Inc. Substituted benzopyran compounds, compositions and uses thereof
CN103879283B (zh) * 2014-03-10 2019-01-15 浙江吉利汽车研究院有限公司 一种电动车辆
JP2017538727A (ja) * 2014-12-18 2017-12-28 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト 癌の治療に有用な２，３−ジフェニルクロメンの誘導体
WO2016174551A1 (en) 2015-04-27 2016-11-03 Pfizer Inc. Anti-estrogenic compounds
US10053451B2 (en) 2015-05-26 2018-08-21 Genentech, Inc. Heterocyclic estrogen receptor modulators and uses thereof
IL283559B (en) * 2015-10-27 2022-07-01 Sun Pharma Advanced Res Co Ltd New heterocyclic anti-estrogens
KR20220046586A (ko) * 2019-07-22 2022-04-14 썬 파마 어드밴스트 리서치 컴패니 리미티드 선택적 에스트로겐 수용체 분해제

Also Published As

Publication number Publication date
PE20221588A1 (es) 2022-10-10
CN114302879A (zh) 2022-04-08
ZA202201157B (en) 2023-07-26
US20210024504A1 (en) 2021-01-28
IL290036A (en) 2022-03-01
CL2022000156A1 (es) 2022-11-18
US11014915B2 (en) 2021-05-25
US20210261534A1 (en) 2021-08-26
JP2022541938A (ja) 2022-09-28
CA3148592A1 (en) 2021-01-28
EP4003525A1 (en) 2022-06-01
AU2020317099A1 (en) 2022-02-24
WO2021014386A1 (en) 2021-01-28
KR20220046586A (ko) 2022-04-14
BR112022001285A2 (pt) 2022-03-22

Similar Documents

Publication Publication Date Title
MX2022001013A (es) Degradador selectivo del receptor de estrogeno.
CR20210501A (es) Inhibidores de la proteína tirosina fosfatasa
IL287945A (en) Compounds for the treatment of Huntington's disease
PH12015502323A1 (en) Enantiomers of spiro-oxindole compounds and their uses as therapeutic agents
EA201792394A2 (ru) Производные 2-(2,4,5-замещенного анилино)пиримидина в качестве модуляторов egfr, полезных для лечения рака
PE20020917A1 (es) Derivados de imidazol como bloqueadores del receptor n-metil-d-aspartato
ZA202301275B (en) Indole compounds as androgen receptor modulators
EP2966065A3 (en) Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
WO2008144483A3 (en) Agents for treating disorders involving modulation of ryanodine receptors
NZ595738A (en) Benzimidazole-piperidine-cyclohexane derivatives which have activity at M1 receptor and their uses in medicine
MA30604B1 (fr) Agonistes de ep2
WO2020081410A3 (en) Radioligands for imaging the lpa1 receptor
BR112021022216A2 (pt) Ácido 6-(2,4-diclorofenil)-5-[4-[(3s)-1-(3-fluoropropil)pirrolidin-3-il]oxifenil]-8,9-di-hidro-7h-benzo[7]anuleno-2-carboxílico para uso em pacientes com câncer de mama metastático ou avançado
MY172729A (en) Pharmaceutical formulations
IL290177A (en) History of 4,2,1-oxadiazol-5-one for cancer therapy
DE602005007765D1 (de) Neue indol- oder benzimidazol-derivate
MX2021002109A (es) Pirrolo [2,3-b] piridina 4-sustituida como moduladores erbb utiles para tratar el cancer.
SA520420382B1 (ar) مُعدِّلات تفارغية موجبة تجاه مستقبل دوبامين 1
MA32356B1 (fr) Utilisation de la dronédarone ou un sel pharmaceutiquement acceptable de celle-ci, pour la préparation d'un médicament permettant la régulation du niveau de potassium dans le sang
MX2007011280A (es) Dipirazoles como farmacos del sistema nervioso central.
MX2020008523A (es) Compuesto que tiene actividad agonista del receptor esfingosina-1-fosfato [(2s,3r,4e)-2-amino-3-hidroxioctadec-4-enil- 1-fosfato (s1p5).
HK1106494A1 (en) Aminomethyl substituted bicyclic aromatic compounds suitable for treating disorders that respond to modulation of the dopamine d3 receptor
MX2021007687A (es) Sales novedosas de degradadores selectivos de receptores de estrogeno.
PE20040591A1 (es) Derivados de oxazol como agonistas de los receptores pparo y/o pparô
MA45665B1 (fr) Dérivés d'éthynyle